Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Trump Criticizes ABC, NBC and CNN for Limiting Coverage of Election Speech 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Seven & i Eyes Żabka Stake in Major European Expansion Push 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Mikron H1 2026 Sales Fall 5.9% as Automation Weakness Weighs on Profit 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Sam Altman Admits OpenAI Missteps, Promises Major AI Comeback Focused on User Freedom 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Moonshot Launches Kimi K3, China's Largest Open-Source AI Model 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
GameStop Raises eBay Stake to 9.8% as Ryan Cohen Pushes $56 Billion Takeover Bid 
Leading pharmaceutical giants Pfizer and AstraZeneca have unveiled significant investment plans for France, totaling almost $1 billion. These announcements were made in anticipation of the annual 'Choose France' business summit, signaling a robust vote of confidence in the French economy by two of the world's foremost healthcare companies.
Pfizer's Pledge to French R&D
MSN reported that Pfizer has committed to investing 500 million euros ($538.5 million) in France, focusing on enhancing its research and development (R&D) capabilities within the country. This move aims to solidify France's position as a key player in the global healthcare research landscape, significantly boosting the local economy and job market.
AstraZeneca's Dunkirk Investment
Similarly, AstraZeneca announced an investment of $388 million to develop its Dunkirk site. This financial infusion is expected to expand the company's manufacturing and production capacities in France, further establishing the country as a critical hub in AstraZeneca's international operations.
The 'Choose France' Initiative
CNBC noted that these announcements arrived just as President Emmanuel Macron was gearing up to inaugurate the 'Choose France' event on Monday. Aiming to attract major overseas businesses and investors, the initiative underscores France's ambition to strengthen its appeal as a global business and investment destination.
Earlier statements also highlighted Morgan Stanley's creation of 100 new jobs in Paris and commitments from other international firms, such as German aviation innovator Lilium.
France's Global Business Ambition
Under President Macron's leadership, France is keen to enhance its stature as a premier European business capital, competing against traditional heavyweights like New York and London. Despite Paris's 14th place ranking in the recent Z/Yen global financial centers survey, these substantial investments by Pfizer and AstraZeneca are poised to contribute significantly to France's ambition of climbing the ranks as a top destination for global finance and business.
Photo: Pfizer Newsroom
